{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:40:10Z","timestamp":1749750010486,"version":"3.41.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,12]]},"DOI":"10.7759\/cureus.85857","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T16:59:51Z","timestamp":1749747591000},"source":"Crossref","is-referenced-by-count":0,"title":["Cerebral Metastasis of a Gastrointestinal Stromal Tumor: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Diogo D","family":"Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabete","family":"Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Daniela","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri GD","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347:472-80. 10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich MC","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, et al.. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21:4342-9. 10.1200\/JCO.2003.04.190","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000333403","article-title":"Brain metastasis from gastrointestinal stromal tumor: a case report and review of the literature","volume":"5","author":"Naoe H","year":"2011","unstructured":"Naoe H, Kaku E, Ido Y, et al.. Brain metastasis from gastrointestinal stromal tumor: a case report and review of the literature. Case Rep Gastroenterol. 2011, 5:583-9. 10.1159\/000333403","journal-title":"Case Rep Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial","volume":"30","author":"George S","year":"2012","unstructured":"George S, Wang Q, Heinrich MC, et al.. Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012, 30:2401-7. 10.1200\/JCO.2011.39.9394","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke CD","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, et al.. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26:626-32. 10.1200\/JCO.2007.13.4452","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay JY","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, et al.. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21:923-34. 10.1016\/S1470-2045(20)30168-6","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35952","article-title":"Intracranial metastasis of gastrointestinal stromal tumors: a literature review of published case reports and case presentation","volume":"10","author":"Lee ZD","year":"2024","unstructured":"Lee ZD, Loh DD, Yang VS, Bin Harunal Rashid MF, Chen MW. Intracranial metastasis of gastrointestinal stromal tumors: a literature review of published case reports and case presentation. Heliyon. 2024, 10:e35952. 10.1016\/j.heliyon.2024.e35952","journal-title":"Heliyon"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi212","article-title":"Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate","volume":"36","author":"Ryu MH","year":"2006","unstructured":"Ryu MH, Lee JL, Chang HM, et al.. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol. 2006, 36:17-24. 10.1093\/jjco\/hyi212","journal-title":"Jpn J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal stromal tumors","volume":"36","author":"von Mehren M","year":"2018","unstructured":"von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol. 2018, 36:136-43. 10.1200\/JCO.2017.74.9705","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu H","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al.. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012, 307:1265-72. 10.1001\/jama.2012.347","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355464-cerebral-metastasis-of-a-gastrointestinal-stromal-tumor-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T16:59:51Z","timestamp":1749747591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355464-cerebral-metastasis-of-a-gastrointestinal-stromal-tumor-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.85857","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}